JP5662766B2 - 癌関連タンパク質を標的とするRNAiプローブ - Google Patents
癌関連タンパク質を標的とするRNAiプローブ Download PDFInfo
- Publication number
- JP5662766B2 JP5662766B2 JP2010250838A JP2010250838A JP5662766B2 JP 5662766 B2 JP5662766 B2 JP 5662766B2 JP 2010250838 A JP2010250838 A JP 2010250838A JP 2010250838 A JP2010250838 A JP 2010250838A JP 5662766 B2 JP5662766 B2 JP 5662766B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- clu
- clusterin
- sirna
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
カルシュ(Carthew)ら、Current Opinions in Cell Biology 13、244〜248頁(2001)
エルバシル(Elbashir)ら、Nature 411、494〜498頁(2001)
1)細胞の調製
抗生物質(ペニシリン/ストレプトマイシン)を含まない5%のFBSを含む適当な培地中のLNCaP細胞0.5×106個を(PC3細胞では、ウェル当たり0.3×106個の密度で)6穴プレートの各ウェルに播く。
40〜50%コンフルエントになるまで、細胞を37ECの加湿下5%CO2インキュベータ内でインキュベートする。
2)siRNAの調製
以下のsiRNA希釈液を微量遠心チューブに調製する。各ウェル当たり、0.01〜100nM。
3)以下のトランスフェクション試薬希釈液を微量遠心チューブに調製する。
6穴プレートの各ウェルについて、OligoFECTAMINE(商標)試薬4mlをOPTI−MEM(商標)11mlで希釈し、室温で10分間インキュベートする。
4)希釈したOligoFECTAMINE(商標)を、希釈したsiRNA二本鎖希釈液と合わせて、反転により穏やかに混合する。
5)室温で20分インキュベートする。
6)ウェルから培地を取り除き、Opti−MEM(商標)800mlと交換する。
7)細胞にトランスフェクション複合体200mlを上層する。
8)37℃のCO2インキュベータ内で4時間インキュベートする。
9)15%FBSを含む培地500mlを添加する。
10)24時間後にリアルタイムPCRにより遺伝子発現をチェックするか、又は
11)1、6、12、24、48、72及び96時間後にウエスタンブロットによりタンパク質発現をチェックする。
Claims (5)
- 各々の鎖が23以下の塩基長を有し、標的遺伝子の転写産物であるmRNAの分解を仲介するか翻訳を阻害するのに有効な配列を有する二重鎖のRNA分子であって、前記標的遺伝子がクラステリンをコードする遺伝子であり、該二重鎖RNA分子の各々の鎖がRNA部分とDNA部分を含み、該RNA部分はそれぞれ、
配列番号1のヌクレオチド1〜19及び配列番号2のヌクレオチド1〜19
からなる相補配列を含む、
上記RNA分子。 - 各々の鎖が23以下の塩基長を有し、標的遺伝子の転写産物であるmRNAの分解を仲介するか翻訳を阻害するのに有効な配列を有する二重鎖のRNA分子であって、前記標的遺伝子が、クラステリンをコードする遺伝子であり、前記二重鎖RNA分子の鎖がそれぞれ、
配列番号1及び配列番号2、
からなる配列を含む、
上記RNA分子。 - 前記二重鎖RNA分子の鎖がそれぞれ、
配列番号1及び配列番号2、
からなる配列からなる請求項2に記載のRNA分子。 - 請求項1から3までのいずれか一項に記載のRNA分子及び薬学的に許容される担体を含む医薬品組成物。
- 前記の薬学的に許容される担体が無菌注射液である請求項4に記載の医薬品組成物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40519302P | 2002-08-21 | 2002-08-21 | |
US60/405,193 | 2002-08-21 | ||
US40815202P | 2002-09-03 | 2002-09-03 | |
US60/408,152 | 2002-09-03 | ||
US47238703P | 2003-05-20 | 2003-05-20 | |
US60/472,387 | 2003-05-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501198A Division JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするRNAiプローブ |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013067754A Division JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするRNAiプローブ |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011036267A JP2011036267A (ja) | 2011-02-24 |
JP5662766B2 true JP5662766B2 (ja) | 2015-02-04 |
Family
ID=31950539
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501198A Expired - Fee Related JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2010128382A Expired - Fee Related JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2010250838A Expired - Fee Related JP5662766B2 (ja) | 2002-08-21 | 2010-11-09 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2013067754A Pending JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするRNAiプローブ |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005501198A Expired - Fee Related JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするRNAiプローブ |
JP2010128382A Expired - Fee Related JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするRNAiプローブ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013067754A Pending JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするRNAiプローブ |
Country Status (10)
Country | Link |
---|---|
US (5) | US8252918B2 (ja) |
EP (2) | EP1532249A2 (ja) |
JP (4) | JP4717633B2 (ja) |
KR (3) | KR101212512B1 (ja) |
AU (1) | AU2003258426B2 (ja) |
CA (2) | CA2882443C (ja) |
IL (3) | IL166658A (ja) |
NO (2) | NO334573B1 (ja) |
NZ (1) | NZ552872A (ja) |
WO (1) | WO2004018676A2 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU227190B1 (en) | 1999-02-26 | 2010-10-28 | Univ British Columbia | Trpm-2 antisense therapy |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
ATE402999T1 (de) | 2002-01-17 | 2008-08-15 | Univ British Columbia | Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung |
CA2882443C (en) * | 2002-08-21 | 2016-12-13 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
ATE478142T1 (de) * | 2002-08-21 | 2010-09-15 | Univ British Columbia | Behandlung von melanomen durch reduktion der clusterin menge |
US7635673B2 (en) | 2003-03-25 | 2009-12-22 | The Board Of Trustees Of The University Of Illinois | Methods of inhibiting tumor cell proliferation |
US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
US20050019918A1 (en) * | 2003-06-03 | 2005-01-27 | Hidetoshi Sumimoto | Treatment of cancer by inhibiting BRAF expression |
JP2005013221A (ja) * | 2003-06-03 | 2005-01-20 | Keio Gijuku | Braf発現抑制を利用した癌の治療 |
MXPA06010667A (es) * | 2004-03-19 | 2007-07-04 | Penn State Res Found | Metodos combinatorios y composiciones para el tratamiento de melanoma. |
US8710020B2 (en) | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
EP2298896A1 (en) * | 2004-06-22 | 2011-03-23 | The Board of Trustees of the University of Illinois | Methods of inhibiting tumor cell proliferation with FOXM1 siRNA |
TWI661199B (zh) * | 2004-07-23 | 2019-06-01 | 太平洋愛吉生技股份有限公司 | 檢測膀胱癌之尿液標記物 |
WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
EP1814595B1 (en) * | 2004-11-23 | 2014-01-08 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
EP1937815B1 (en) * | 2005-09-13 | 2015-05-13 | National Research Council of Canada | Methods and compositions for modulating tumor cell activity |
US8029980B2 (en) | 2006-09-29 | 2011-10-04 | The Board Of Trustees Of The University Of Illinois | Identification and use of agents that modulate oncogenic transcription agent activity |
EP2117557A4 (en) * | 2007-01-16 | 2011-01-19 | Burnham Inst Medical Research | COMPOSITIONS AND METHODS FOR THE TREATMENT OF COLORECTAL CANCER |
WO2008094516A2 (en) * | 2007-01-29 | 2008-08-07 | City Of Hope | Multi-targeting short interfering rnas |
EP2121923A1 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
US8217161B2 (en) * | 2008-04-22 | 2012-07-10 | Clemson University Research Foundation | Methods of inhibiting multiple cytochrome P450 genes with siRNA |
DK2504363T3 (da) | 2009-11-24 | 2019-07-29 | Alethia Biotherapeutics Inc | Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen |
EP3301176B1 (en) | 2011-02-11 | 2019-09-25 | The Rockefeller University | Method for identifying nucleic acids regulating metastasation |
JP2015512877A (ja) | 2012-02-22 | 2015-04-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌を治療するためのクラステリン阻害剤とegfr阻害剤の併用 |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
CN106282185B (zh) * | 2016-08-18 | 2020-06-26 | 广州市锐博生物科技有限公司 | 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5736580A (en) * | 1980-08-13 | 1982-02-27 | Hitachi Ltd | Protecting method for converter |
AU663702B2 (en) * | 1991-03-06 | 1995-10-19 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
US20020086386A1 (en) * | 1997-03-04 | 2002-07-04 | Kamb Carl Alexander | B-catenin assays, and compositions therefrom |
US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
HU227190B1 (en) * | 1999-02-26 | 2010-10-28 | Univ British Columbia | Trpm-2 antisense therapy |
WO2000069454A1 (en) * | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
AU772480B2 (en) | 1999-07-19 | 2004-04-29 | University Of British Columbia, The | Antisense therapy for hormone-regulated tumors |
US6140126A (en) * | 1999-10-26 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of Y-box binding protein 1 expression |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
WO2001068836A2 (en) * | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
JP5500750B2 (ja) | 2000-03-30 | 2014-05-21 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | Rna干渉のrna配列特異的メディエータ |
HU229207B1 (en) | 2000-09-14 | 2013-09-30 | Univ British Columbia | Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine regulated tumor therapy |
US20040259247A1 (en) * | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
EP1354038A2 (en) | 2000-12-28 | 2003-10-22 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
ATE402999T1 (de) * | 2002-01-17 | 2008-08-15 | Univ British Columbia | Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung |
CA2882443C (en) * | 2002-08-21 | 2016-12-13 | The University Of British Columbia | Rnai probes targeting cancer-related proteins |
ATE478142T1 (de) | 2002-08-21 | 2010-09-15 | Univ British Columbia | Behandlung von melanomen durch reduktion der clusterin menge |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
-
2003
- 2003-08-21 CA CA2882443A patent/CA2882443C/en not_active Expired - Fee Related
- 2003-08-21 AU AU2003258426A patent/AU2003258426B2/en not_active Ceased
- 2003-08-21 KR KR1020057002963A patent/KR101212512B1/ko not_active IP Right Cessation
- 2003-08-21 KR KR1020107028249A patent/KR101117673B1/ko not_active IP Right Cessation
- 2003-08-21 US US10/646,436 patent/US8252918B2/en not_active Expired - Fee Related
- 2003-08-21 WO PCT/CA2003/001277 patent/WO2004018676A2/en active Application Filing
- 2003-08-21 NZ NZ552872A patent/NZ552872A/en not_active IP Right Cessation
- 2003-08-21 EP EP03792075A patent/EP1532249A2/en not_active Ceased
- 2003-08-21 JP JP2005501198A patent/JP4717633B2/ja not_active Expired - Fee Related
- 2003-08-21 KR KR1020117025408A patent/KR101238701B1/ko not_active IP Right Cessation
- 2003-08-21 EP EP10010458.7A patent/EP2263679B1/en not_active Expired - Lifetime
- 2003-08-21 CA CA2494766A patent/CA2494766C/en not_active Expired - Fee Related
-
2005
- 2005-02-02 IL IL166658A patent/IL166658A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051423A patent/NO334573B1/no not_active IP Right Cessation
-
2006
- 2006-02-23 US US11/276,300 patent/US7964717B2/en not_active Expired - Fee Related
-
2008
- 2008-05-06 US US12/116,083 patent/US7820635B2/en not_active Expired - Fee Related
-
2009
- 2009-02-22 IL IL197159A patent/IL197159A/en not_active IP Right Cessation
-
2010
- 2010-06-04 JP JP2010128382A patent/JP5171887B2/ja not_active Expired - Fee Related
- 2010-07-28 US US12/845,521 patent/US8759308B2/en not_active Expired - Fee Related
- 2010-11-09 JP JP2010250838A patent/JP5662766B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-24 US US13/404,741 patent/US9487777B2/en not_active Expired - Fee Related
- 2012-09-14 NO NO20121038A patent/NO337130B1/no not_active IP Right Cessation
-
2013
- 2013-03-28 JP JP2013067754A patent/JP2013150624A/ja active Pending
-
2014
- 2014-06-24 IL IL233352A patent/IL233352A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5662766B2 (ja) | 癌関連タンパク質を標的とするRNAiプローブ | |
JP5841332B2 (ja) | 細胞増殖阻害剤 | |
CA3161513A1 (en) | Antisense oligonucleotide targeting linc00518 for treating melanoma | |
Xing et al. | Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids | |
AU2007216630B2 (en) | RNAi probes targeting cancer-related proteins | |
JP2010529852A (ja) | 癌治療のためのNuMAのRNAi媒介ノックダウン | |
NZ538287A (en) | RNAi probes targeting cancer-related proteins | |
CA2680058C (en) | Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity | |
US9464291B2 (en) | Methods and compositions for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121030 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141006 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141020 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5662766 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |